Cargando…

Design, Synthesis, Pharmacological Activities, Structure–Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones

[Image: see text] This study is aimed to synthesize morpholine- and thiazolidine-based novel 5-(substituted)benzylidene)-2-(morpholinoimino)-3-phenylthiazolidin-4-ones (3–26) and characterized by molecular spectroscopy. The synthesized compounds were subjected to antioxidant activity with anticholin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sıcak, Yusuf, Aktar, Bedriye Seda Kurşun, Yılmaz, Gizem Tatar, Öztürk, Fatma Aydoğmuş, Öztürk, Mehmet, Tok, Tuğba Taşkın, Emre, Emine Elçin Oruç
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586451/
https://www.ncbi.nlm.nih.gov/pubmed/37867693
http://dx.doi.org/10.1021/acsomega.3c05928
_version_ 1785123162780860416
author Sıcak, Yusuf
Aktar, Bedriye Seda Kurşun
Yılmaz, Gizem Tatar
Öztürk, Fatma Aydoğmuş
Öztürk, Mehmet
Tok, Tuğba Taşkın
Emre, Emine Elçin Oruç
author_facet Sıcak, Yusuf
Aktar, Bedriye Seda Kurşun
Yılmaz, Gizem Tatar
Öztürk, Fatma Aydoğmuş
Öztürk, Mehmet
Tok, Tuğba Taşkın
Emre, Emine Elçin Oruç
author_sort Sıcak, Yusuf
collection PubMed
description [Image: see text] This study is aimed to synthesize morpholine- and thiazolidine-based novel 5-(substituted)benzylidene)-2-(morpholinoimino)-3-phenylthiazolidin-4-ones (3–26) and characterized by molecular spectroscopy. The synthesized compounds were subjected to antioxidant activity with anticholinesterase, tyrosinase, and urease inhibition activities and evaluated the structure–activity relationship (SAR) of enzyme inhibition activities. Compound 11 was found to be the most active antioxidant. In anticholinesterase inhibition, compound 12 (IC(50): 17.41 ± 0.22 μM) was the most active against AChE, while compounds 3–26 ( except 3, 8, and 17) showed notable activity against BChE. Compounds 17 (IC(50): 3.22 ± 0.70 mM), 15 (IC(50): 5.19 ± 0.03 mM), 24 (IC(50): 7.21 ± 0.27 mM), 23 (IC(50): 8.05 ± 0.11 mM), 14 (IC(50): 8.10 ± 0.22 mM), 25 (IC(50): 8.40 ± 0.64 mM), 26 (IC(50): 8.76 ± 0.90 mM), and 22 (IC(50): 9.13 ± 0.55 mM) produced higher tyrosinase inhibition activity. In urease inhibition activity, compounds 20 (IC(50): 16.79 ± 0.19 μM), 19 (IC(50): 18.25 ± 0.50 μM), 18 (IC(50): 20.24 ± 0.77 μM), 26 (IC(50): 21.51 ± 0.44 μM), 25 (IC(50): 21.70 ± 0.06 μM), and 24 (IC(50): 22.49 ± 0.11 μM) demonstrated excellent activities. Besides, the molecular docking study was applied to better understand the inhibitory mechanism between (1–26) compounds and enzymes at the molecular level. According to the results of this study, the synthesized compounds exhibited a better binding affinity toward these enzymes compared to the positive control. Further, molecular mechanics Poisson–Boltzmann surface area (MM/PBSA) binding free energy and molecular dynamics (MD) simulation analyses were performed for AChE with compound 26, which showed high inhibitory activity in silico and in vitro studies. In conclusion, novel morpholine and thiazolidine-based derivative compounds may be pharmacologically effective agents for AChE, BChE, tyrosinase, and urease enzymes.
format Online
Article
Text
id pubmed-10586451
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-105864512023-10-20 Design, Synthesis, Pharmacological Activities, Structure–Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones Sıcak, Yusuf Aktar, Bedriye Seda Kurşun Yılmaz, Gizem Tatar Öztürk, Fatma Aydoğmuş Öztürk, Mehmet Tok, Tuğba Taşkın Emre, Emine Elçin Oruç ACS Omega [Image: see text] This study is aimed to synthesize morpholine- and thiazolidine-based novel 5-(substituted)benzylidene)-2-(morpholinoimino)-3-phenylthiazolidin-4-ones (3–26) and characterized by molecular spectroscopy. The synthesized compounds were subjected to antioxidant activity with anticholinesterase, tyrosinase, and urease inhibition activities and evaluated the structure–activity relationship (SAR) of enzyme inhibition activities. Compound 11 was found to be the most active antioxidant. In anticholinesterase inhibition, compound 12 (IC(50): 17.41 ± 0.22 μM) was the most active against AChE, while compounds 3–26 ( except 3, 8, and 17) showed notable activity against BChE. Compounds 17 (IC(50): 3.22 ± 0.70 mM), 15 (IC(50): 5.19 ± 0.03 mM), 24 (IC(50): 7.21 ± 0.27 mM), 23 (IC(50): 8.05 ± 0.11 mM), 14 (IC(50): 8.10 ± 0.22 mM), 25 (IC(50): 8.40 ± 0.64 mM), 26 (IC(50): 8.76 ± 0.90 mM), and 22 (IC(50): 9.13 ± 0.55 mM) produced higher tyrosinase inhibition activity. In urease inhibition activity, compounds 20 (IC(50): 16.79 ± 0.19 μM), 19 (IC(50): 18.25 ± 0.50 μM), 18 (IC(50): 20.24 ± 0.77 μM), 26 (IC(50): 21.51 ± 0.44 μM), 25 (IC(50): 21.70 ± 0.06 μM), and 24 (IC(50): 22.49 ± 0.11 μM) demonstrated excellent activities. Besides, the molecular docking study was applied to better understand the inhibitory mechanism between (1–26) compounds and enzymes at the molecular level. According to the results of this study, the synthesized compounds exhibited a better binding affinity toward these enzymes compared to the positive control. Further, molecular mechanics Poisson–Boltzmann surface area (MM/PBSA) binding free energy and molecular dynamics (MD) simulation analyses were performed for AChE with compound 26, which showed high inhibitory activity in silico and in vitro studies. In conclusion, novel morpholine and thiazolidine-based derivative compounds may be pharmacologically effective agents for AChE, BChE, tyrosinase, and urease enzymes. American Chemical Society 2023-10-04 /pmc/articles/PMC10586451/ /pubmed/37867693 http://dx.doi.org/10.1021/acsomega.3c05928 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Sıcak, Yusuf
Aktar, Bedriye Seda Kurşun
Yılmaz, Gizem Tatar
Öztürk, Fatma Aydoğmuş
Öztürk, Mehmet
Tok, Tuğba Taşkın
Emre, Emine Elçin Oruç
Design, Synthesis, Pharmacological Activities, Structure–Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones
title Design, Synthesis, Pharmacological Activities, Structure–Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones
title_full Design, Synthesis, Pharmacological Activities, Structure–Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones
title_fullStr Design, Synthesis, Pharmacological Activities, Structure–Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones
title_full_unstemmed Design, Synthesis, Pharmacological Activities, Structure–Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones
title_short Design, Synthesis, Pharmacological Activities, Structure–Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones
title_sort design, synthesis, pharmacological activities, structure–activity relationship, and in silico studies of novel 5-substituted-2-(morpholinoimino)-thiazolidin-4-ones
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586451/
https://www.ncbi.nlm.nih.gov/pubmed/37867693
http://dx.doi.org/10.1021/acsomega.3c05928
work_keys_str_mv AT sıcakyusuf designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones
AT aktarbedriyesedakursun designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones
AT yılmazgizemtatar designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones
AT ozturkfatmaaydogmus designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones
AT ozturkmehmet designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones
AT toktugbataskın designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones
AT emreemineelcinoruc designsynthesispharmacologicalactivitiesstructureactivityrelationshipandinsilicostudiesofnovel5substituted2morpholinoiminothiazolidin4ones